Authors
Latest:
The Field Guide to Pharmaceutical Powder Characterization (July 2023)If you want to learn more about the physical characterization of your pharmaceutical powders, download this free e-book. You will find real measurement data that has been collected from a range of characterization methods, including particle, surface area and pore size analysis, powder rheology, and X-ray diffraction. Deepening your understanding of bulk particle properties is just the first step to get more predictable formulations and optimized processes.
Latest:
Nitrosamine Mitigation: A Path to Regulatory ComplianceIn the wake of the Food and Drug Administration's (FDA's) latest guidance on nitrosamine contamination, ensuring compliance and safeguarding pharmaceutical products is more critical than ever. This ebook provides a comprehensive roadmap for understanding nitrosamine risks and offers actionable strategies to mitigate potential impurities. Through expert insights from Adare Pharma Solutions, you’ll learn how to remain compliant, identify risks, and implement cutting-edge strategies for nitrosamine mitigation.
Latest:
Navigating an Uncertain Regulatory Environment for mRNA-based ProductsRegulations for mRNA products are evolving as the market for mRNA expands.
Latest:
Raman Detects Pharma Processing FingerprintsRaman spectroscopy delivers real time, non-destructive process insights for critical process parameters to monitor pharmaceutical manufacturing.
Latest:
Rapid Sterility Methods for CAR T-cell TherapiesA combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
Latest:
Effective and Efficient Weighing of Potent CompoundsThe advantages of using an automated powder dispensing system in a ventilated balance enclosure for efficient handling and effective containment of potent compounds are discussed.
Latest:
Manufacturing Considerations for Sourcing GMP Fermentation ServicesThe authors describe the critical aspects of an ideal fermentation services provider.
Latest:
The Lighthouse Effect: Using Technology to Improve Life Sciences ManufacturingLighthouse manufacturing techniques utilize technology and automation to streamline production.
Latest:
Changing the Dynamic of CROsThrough its educational and networking opportunities, the American Association of Pharmaceutical Scientists plays an important role in partnering throughout the drug- development and commercialization process.
Latest:
Industrial Applications of Whole-Cell BiocatalysisRecombinant microbial whole-cell biocatalysis is a valuable approach for producing enantiomerically pure intermediates. The authors examine several groups of enzymes using this approach: dehydrogenases, hydantoinases, and acylases.
Latest:
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding ApplicationsThis paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Latest:
Dielectric Spectroscopy: Choosing the Right ApproachThis tutorial paper is meant to aid in dielectric-sensor selection
Latest:
Thermal fingerprinting: a way to optimize lyophilizationFreeze drying is widely used in pharmaceuticals to improve the long-term storage stability of labile drugs.
Latest:
The current and future market for SNPsSingle nucleotide polymorphisms (SNPs) are responsible for more than 80% of the variations between individuals, and are present throughout most genes and other important sequences in the human body, which makes them ideal for tracking down correlations between genotype and phenotype.
Latest:
The Impact of SARS-CoV-2 on Biomanufacturing OperationsThis article presents the results of a survey conducted to gain insight on the impact of the COVID-19 pandemic on biomanufacturing operations.
Latest:
Change management: common failures and a checklist for improvementThough the pharma industry has improved its change management processes, there are still opportunities for improvement.
Latest:
Common FDA 483 Observations for Combination ProductsAny improper validation of methods is likely to result in regulatory agency deficiencies that range in degree of severity.
Latest:
Development of a Validated Method of Testing for NDMA in RanitidineThis article describes a validated method, using liquid chromatography/mass spectrometry, for detecting the carcinogenic impurity NDMA (N-nitrosodimethylamine) in ranitidine that meets and exceeds FDA’s limit of detection and limit of quantitation requirements.
Latest:
A Harmonized Approach to Performing a Risk-Based Audit Trail ReviewThe IQ Working Group has defined a pragmatic risk-based approach to audit trail review, where it is only required for high impact GxP data.
Latest:
Leveraging Integrated Patient-Centric Innovations When Developing Today’s BiologicsHeidi Casaletto, Vice President of Global Marketing, Catalent, comments on the significance of developing biologics with a 'patient first' philosphy.
Latest:
Recent Options for Phase 1 Formulation Development and Clinical Trial Material SupplyTo meet the demands of early-stage development, contract research organizations can evaluate various dosage-form options. The author examines various methods of capsule filling, including binary blends.
Latest:
Suitability-for-Use Considerations for Prefilled SyringesThe nature of their application and their mode of use mean that prefilled syringes meet the regulatory definitions of immediate packaging or container–closure systems.
Latest:
Ongoing Analytical Procedure Performance Verification—Stage 3 of USP<1220>Analytical procedure performance can be continually verified by risk-based monitoring of performance related data.
Latest:
Driving Consistency in Validation ManagementWith data integrity regulatory violations on the rise, there is a need for better and more consistent validation management practices.
Latest:
Industry 1VQ Solutions: Replace Identity (ID) Testing of Incoming Liquid Drug Substance with ID by Visual VerificationA Post Approval Change (PAC) to replace identity (ID) testing of incoming liquid drug substance with ID by visual inspection is considered a low risk provided questioned listed in this example have been answered favorably. In that case the PAC can be downgraded from a prior approval to a notification to health authorities, and managed in the PQS with immediate implementation effect.
